Updates
Press Release
Lupin LimitedLUPIN · Filed with the exchange
Lupin secured U.S.
FDA approval for Sodium Zirconium Cyclosilicate Oral Suspension, a drug for hyperkalemia.
The reference product had estimated annual sales of USD 56.8 Cr, indicating a significant market opportunity.
No comments yet. Be the first.